Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexketoprofen trometamol is the water-soluble salt form of dexketoprofen, which is the active right-handed (dextrorotatory) enantiomer of ketoprofen. It is a nonsteroidal anti-inflammatory drug (NSAID) used for short-term treatment of mild to moderate pain, including musculoskeletal pain, dysmenorrhea, dental pain, migraine headaches, and postoperative pain[1][3][5][6]. Dexketoprofen works by inhibiting both cyclooxygenase 1 and 2 (COX‑1 and COX‑2), thereby reducing prostaglandin synthesis involved in inflammation, pain, and fever[1][3][5]. The drug has a rapid onset of action—typically within 30 minutes—and can be administered orally or intravenously. It provides effective analgesia with an opioid-sparing effect in acute settings[6]. Dexketoprofen trometamol was developed as a chiral switch from racemic ketoprofen to improve therapeutic value and reduce gastrointestinal side effects[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexketoprofen trometamol.